Best Genomics Companies in Pennsylvania, United States
The 88 best Genomics companies in Pennsylvania, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Tmunity Therapeutics.
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Genomics companies in Pennsylvania
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Tmunity Therapeutics Leveraging the immunological potential of T cells to treat a wide range of diseases | $231M | 79 mo ago | 43 | — | — | — | — |
| 2 | Passage Bio Developer of gene therapies for CNS rare diseases | $226M | 57 mo ago | 58 58 → 43 (-26%) | Stephen Squinto Co-Founder | BugHerdQ4MediaElement.js+24 | — | — |
| 3 | Helomics AI-driven platform to develop precisely targeted therapies for cancer patients | $196M | 98 mo ago | 13 | — | — | 2 patents Personalized oncology diagnostics and in‑silico chemotherapy simulation for patient‑specific treatment planning. | — |
| 4 | SwanBio Therapeutics Provider of AAV-based gene therapy for neurological diseases | $133M | 49 mo ago | 47 | — | — | — | — |
| 5 | iECURE Online genetic engineering tool for drug development | $115M | 42 mo ago | 7 | Joseph Truitt CEO | — | — | 1 internship |
| 6 | Limelight Bio Provider of AAV-based gene therapies to treat inherited diseases | $89M | 78 mo ago | — | Sam Hall CEO & Director | — | — | — |
| 7 | Code Biotherapeutics Developer of gene therapies for rare diseases | $85M | 48 mo ago | 41 | Robert Getts Co-Founder & CTO | Cart FunctionalityWixSentry+17 | 25 patents Patents concentrated in chemistry & materials | — |
| 8 | Spark Therapeutics Developer of gene therapy for rare diseases | $83M | 145 mo ago | 822 | — | WordPressApple iCloud MailMySQL+21 | 473 patents Optimizing AAV gene‑therapy vectors, transduction efficiency, and RNAi therapeutics for disease | — |
| 9 | Nucleonics Developing RNAi therapeutics for Hepatitis B and C, using eiRNA technology | $52M | 260 mo ago | — | John Maraganore CEO | — | 46 patents RNAi-based antiviral therapeutics and gene‑silencing platforms for hepatitis viruses | — |
| 10 | Genomind Developer of genetic tests for personalised medicines to enhance mental health treatment | $48M | 16 mo ago | 65 | Bill Brown CEO | WordPressMySQLPHP+28 | 32 patents Pharmacogenomic testing and reporting tools for mental health and drug response | — |
| 11 | XyloCor Therapeutics Developer of gene therapies for the treatment of coronary arterial disease | $43M | 17 mo ago | 18 | Ronald Crystal Co-Founder | Apache HTTP ServerjQueryGoogle Hosted Libraries | — | — |
| 12 | Tavotek Provider of drug discovery platform for different diseases | $35M | 55 mo ago | 23 | — | — | — | — |
| 13 | Fibrocell Science Developer of autologous cell and gene therapies for diseases of the skin, connective tissue and joints | $35M | 90 mo ago | 19 | — | — | — | — |
| 14 | LifeSensors Life science company providing innovative tools for ubiquitin proteasome system research | $21M | 24 mo ago | 19 | — | Cart FunctionalityWooCommerceWordPress+32 | 39 patents Recombinant protein production and ubiquitin‑based assay reagents for biotech research | — |
| 15 | Krystal Biotech Developer of genetic medicines to treat rare diseases | $11M | 37 mo ago | 229 229 → 317 (+38%) | Krish Krishnan CEO | WordPressApple iCloud MailMySQL+25 | 169 patents Ophthalmic and dermatological biologic therapeutics, including CFTR protein delivery and cytokine cancer treatments. | — |
| 16 | Instadiagnostics Point-of-care diagnostics platform delivering rapid, comprehensive healthcare solutions | $11M | 13 mo ago | 5 | Johann deSa Founder | — | — | — |
| 17 | Jbs-science Provider of circulating cell-free DNA (cfDNA) for cancer screening | $10M | 14 mo ago | — | Frank Song Founder | — | — | — |
| 18 | Molecular Detection Molecular diagnostics company focused on rapid, accurate infectious disease detection | $8M | 156 mo ago | — | Aryeh Gassel Co-Founder | — | 26 patents Molecular diagnostic kits for PCR-based detection of antibiotic‑resistant bacteria. | — |
| 19 | PeriphaGen Biopharmaceutical company developing HSV-1 vectors for gene therapy and neurologic diseases | $6M | 146 mo ago | 2 | — | — | 22 patents Patents concentrated in chemistry & materials | — |
| 20 | ARIEL Precision Medicine Precision medicine for complex diseases through advanced genetics and data analysis | $6M | 83 mo ago | 22 | — | WordPressMySQLPHP+29 | — | — |
| 21 | Biomeme Developer of a smartphone-based DNA detection platform | $6M | 109 mo ago | 202 | — | Tailwind CSSAmazon Web ServicesAstro+5 | 89 patents Portable point‑of‑care nucleic acid extraction, amplification, and detection devices for infectious diagnostics | — |
| 22 | Panorama Medicine Provider of drug discovery platform for detecting RNA defects | $6M | 33 mo ago | 5 | — | — | — | — |
| 23 | NeuBase Therapeutics Developer of genetic medicines for rare and common diseases | $5M | 35 mo ago | 2 | — | — | — | — |
| 24 | Globin Solutions Developer of antidotal therapies for human poisonings | $5M | 76 mo ago | 3 | — | — | — | — |
| 25 | Rosetta Genomics MicroRNA-based molecular diagnostics, research laboratory, and testing services for cancer | $4M | 107 mo ago | 86 | — | — | 28 patents MicroRNA therapeutics targeting liver cancer diagnostics and treatment | — |
| 26 | 20n Bio Provider of an AI-assisted platform for drug discovery and development | $3M | 54 mo ago | 5 | Mingfu Zhu Founder & CEO | — | — | — |
| 27 | Man’s Best Friends Therapeutics Developer of vaccines for animal health | $3M | 53 mo ago | 6 | Thomas Tillett CEO & President | — | — | — |
| 28 | Life Length Provides telomere length analysis technology for diagnosis | $3M | 29 mo ago | 74 | Stephen Matlin Founder & CEO | WordPressMySQLPHP+21 | — | — |
| 29 | Targeted Diagnostics & Therapeutics Diagnostic products to detect colorectal cancer and other gastrointestinal diseases | $2M | 123 mo ago | — | Harry Arena Founder & CEO | — | — | — |
| 30 | Liquid Biotech Provider of telomerase-based liquid biopsy tests | $2M | 126 mo ago | 2 | Philip Sass CEO | — | — | — |
| 31 | ExpressCells Developer of gene editing technology using CRISPR | $2M | 62 mo ago | 8 | Oscar Perez-Leal Co-Founder & Managing Director | — | — | — |
| 32 | Hager Biosciences Biopharmaceutical company providing pre-clinical therapeutic leads through agile drug discovery chemistry | $2M | 25 mo ago | 3 | Bel Mekonnen President & CEO | — | 39 patents Small-molecule orexin and kappa‑opioid receptor modulators for neuropsychiatric therapies | — |
| 33 | NanoVision Diagnostics Optical biomarkers for cancer diagnostics | $2M | 149 mo ago | — | Mike Lang Co-Founder & CEO | — | — | — |
| 34 | Aum Lifetech Developer of immunotherapies for a wide of diseases | $1M | 15 mo ago | 9 | — | — | 36 patents Patents concentrated in chemistry & materials | — |
| 35 | Leversense Developing device for detecting AIDS, food toxin and mycoplasma bacteria | $659K | 186 mo ago | — | Paul Horan ex-CEO | — | 4 patents Resonant cantilever biosensors for highly sensitive detection of pathogens and analytes | — |
| 36 | Lenima Field Diagnostics Provider of point-of-care molecular diagnostics tests for infectious disease and cancer | $552K | 73 mo ago | 3 | Wan Shih Co-Founder | — | — | — |
| 37 | Vital Probes Products and technologies for the detection and mitigation of infectious diseases | $424K | 189 mo ago | — | Vito Delvecchio CEO | — | — | — |
| 38 | SCRIPT Biosciences Provider of gene-editing platform for drug development | $274K | 24 mo ago | 5 | Anil Namboodiripad CEO | — | — | — |
| 39 | Ribonova Provider of small molecule drugs against defective t-RNA | $250K | 117 mo ago | — | — | — | 17 patents Therapeutics and diagnostic computing for mitochondrial disease treatment | — |
| 40 | Chip Diagnostics Penn Center for Innovation: University of Pennsylvania's tech transfer and venture arm | $250K | 123 mo ago | 6 | David Issadore Founder | — | — | — |
| 41 | MS2 Array Online platform offering microarray services | $222K | 105 mo ago | 1 | Marvin S. Yu Co-Founder & CEO | — | — | — |
| 42 | Agentase Applications and products that detect chemical and biological agents. | $100K | 160 mo ago | — | Keith LeJeune Founder & CEO | — | 46 patents Antimicrobial self‑decontaminating polymers and enzyme‑based biosensor kits for environmental monitoring | — |
Top 12 Genomics companies in Pennsylvania
#1
Series C · King Of Prussia, Pennsylvania · founded 2009 · 65 employees$47.8Mraised▾
Developer of genetic tests for personalised medicines to enhance mental health treatment. It offers Genomind's PGx test that examines genes related to mental health treatment, providing insights into how a patient may metabolize or respond to different medication. It also offer Mental Health Map a DNA test that assesses genetic predispositions across core mental health capabilities, including mood, focus, and stress responses.
- Feb 2025Grant (prize money)$399.6K
- Sep 2023Grant (prize money)$399.6K
- Apr 2021Series C$6.4M
- Jul 2018Series C$20.6M
#2
Series B · Newtown Square, Pennsylvania · founded 2013 · 18 employees$43.4Mraised▾
XyloCor Therapeutics is developing gene therapies for coronary arterial disease. Its lead candidate, XC001, is for patients with refractory angina with no treatment options, and its secondary product for patients with cardiac tissue damage from heart attacks. XC001 is designed to stimulate the formation of new coronary blood vessels to serve areas of the heart that are not receiving adequate blood supply. The second candidate, XC002 is in the discovery stage and involves the regeneration of cardiac tissue for cases with past heart attacks.
- Jan 2025Series B$67.5M
- Mar 2021Series A$22.6M
- Jan 2021Series A$4M
- Oct 2018Series A$16.8M
#3
Funding Raised · Philadelphia, Pennsylvania · founded 2015 · 5 employees$11Mraised▾
Point-of-care diagnostics platform delivering rapid, comprehensive healthcare solutions. The company provides a diagnostic technology platform designed to empower healthcare professionals with the capability to perform various tests directly at their clinics. This innovative system utilizes a portable, multi-modality reader and application-specific cartridges to deliver timely, accurate, and comprehensive healthcare within a single visit. The platform supports immunoassay, chemistry, and molecular assays, as well as complete blood cell counts. The fully automated system minimizes user errors and provides rapid results, enhancing efficiency and improving patient outcomes. This technology offers a single device solution, reducing the need for multiple systems and extensive training. The platform features wireless connectivity and electronic medical record compatibility, facilitating seamless integration into existing healthcare workflows. This is a B2B tech company in the healthcare industry.
- May 2025Grant (prize money)$4.1M
- Sep 2021Grant (prize money)$1M
- Jul 2020Grant (prize money)$4.1M
- Feb 2020Grant (prize money)$225K
#4
Funding Raised · Pennsylvania Furnace, Pennsylvania · founded 2011$10.4Mraised▾
Provider of circulating cell-free DNA (cfDNA) for cancer screening. The company has developed qPCR assays for tumor DNA markers using cfDNA in urine and blood, and robust methods for cfDNA isolation. The first application is the non-invasive screening and monitoring of hepatocellular carcinoma. Additional diagnostic tests for colon, pancreatic, and lung cancer are also under development.
- Apr 2025Grant (prize money)$604.2K
- Aug 2023Grant (prize money)$406.5K
- Mar 2023Grant (prize money)$595.8K
- Dec 2021Grant (prize money)$604.2K
#5
Funding Raised · Philadelphia, Pennsylvania · founded 2013 · 9 employees$1.4Mraised▾
Developer of immunotherapies for a wide of diseases. The company's FANA RNA silencing platform is centered around 2'Fluoridated Arabinonucleic Acids, which can be used to synthesize oligonucleotides that can efficiently and persistently silence target gene activity. The company is focusing on developing antisense therapeutics based on the FANA platform in the broad areas of Hematology, Oncology, CNS, Kidney, Liver, IBD, GI, autoimmune and inflammatory diseases, cardiovascular diseases, as well as orphan diseases like DMD. The company is also looking at applying its technology to address challenges in agriculture and is collaborating with the USDA to develop non-GMO RNA silencing mediated crop traits against citrus greening for bacteria, insect, and pathogen control.
- Mar 2025Grant (prize money)$400K
- Aug 2022Grant (prize money)$400K
- Aug 2020Grant (prize money)$600K
#6
Funding Raised · Malvern, Pennsylvania · founded 1996 · 19 employees$21.3Mraised▾
Life science company providing innovative tools for ubiquitin proteasome system research. They are dedicated to advancing research through cutting-edge technologies and comprehensive solutions. They offer a wide array of products and services focused on protein degradation pathways, including PROTACs, molecular glues, TUBEs, ubiquitin ligases, deubiquitinating enzymes, and SUMOylation tools. Their offerings span from reagents and assays to custom solutions, supporting drug discovery and basic research. They provide tools for ubiquitination, protein expression, and analysis, catering to diverse research needs in areas like neurodegeneration, cancer, and therapeutic development. They also offer R&D services, including PROTAC development, DUB assays, and mass spectrometry proteomics. They are committed to enabling scientific breakthroughs through their innovative products and expert support.
- 2024Grant (prize money)$300K
- 2020Grant (prize money)$3.2M
- 2019Grant (prize money)$2.3M
- 2017Grant (prize money)$2M
#7
Series A · Philadelphia, Pennsylvania · founded 2020 · 7 employees$115Mraised▾
Online genetic engineering tool for drug development. The company focused on developing in vivo gene insertion therapies for the treatment of rare pediatric liver diseases including ARCUS a mediated therapeutic candidate.
- Nov 2022Series A$65M
- Sep 2021Series A$50M
#8
Acquired · Bala Cynwyd, Pennsylvania · founded 2017 · 47 employees$133Mraised▾
Provider of AAV-based gene therapy for neurological diseases. The company is using an adeno-associated virus (AAV) to deliver therapeutic genes directly to the central nervous system to achieve therapeutic effects. The lead drug candidate is SBT101, which aims to treat adrenomyeloneuropathy (AMN) by targeting the disease-causing mutation in the ABCD1 gene.
- May 2022Series B$56M
- Apr 2020Series A$52M
- Jan 2018Series A$25M
#9
Public · Philadelphia, Pennsylvania · founded 2017 · 58 employees$225.5Mraised▾
Developer of gene therapies for CNS rare diseases. The company has developed AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases. Its lead programs are focused on GM1 gangliosidosis, frontotemporal dementia, and Krabbe disease.
- Sep 2021Post IPO$50M
- Sep 2019Series B$110M
- Feb 2019Series A$115.5M
#10
Acqui-Hired · Philadelphia, Pennsylvania · founded 2015 · 43 employees$231Mraised▾
Tmunity Therapeutics, co-founded by the University of Pennsylvania (Penn), the Perelman School of Medicine at Penn and the University of Pennsylvania Health System, is focused on leveraging the immunological potential of T cells to treat a wide range of diseases. Tmunity is developing novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), universal engineered T cell platforms, and Chimeric Antigen Receptor (CAR) therapies to control T cell activation and direction in vivo, as well as proprietary technologies to activate, expand, and genetically engineer T cells from peripheral blood, cord blood and tumors. The company is rapidly advancing personalized next-generation immunotherapies for oncology, infectious diseases and autoimmune disease toward the clinic. In addition, Tmunity has secured its own manufacturing facility in Norristown, PA, that will enable process improvement and production scale-up to support future multi-center clinical studies across diverse therapeutic indications.
- Oct 2019Series B$75M
- Apr 2018Series A$35M
- Jan 2018Series A$100M
- Jan 2018Series A$5M
#11
Series A · Hatfield, Pennsylvania · founded 2020 · 41 employees$85Mraised▾
Developer of gene therapies for rare diseases. The therapies are developed for the treatment of Duchenne muscular dystrophy and type 1 diabetes. The company has a non-viral gene delivery platform 3DNA that delivers genes of all sizes, improves cellular targeting, and reduces immunogenicity.
- Jun 2022Series A$75M
- Apr 2021Seed$10M
#12
Funding Raised · Bethlehem, Pennsylvania · founded 2008 · 3 employees$1.8Mraised▾
Biopharmaceutical company providing pre-clinical therapeutic leads through agile drug discovery chemistry platforms. They offer unique small fragment molecules, improvement of drug-like properties, rapid med chem lead generation and optimization, and drug rescue. They focus on discovering licensable pre-clinical leads for unmet medical needs through collaborative partnerships. Their services include lead generation, optimization, profile improvement, methodology development, and project management. They are a preclinical-stage drug discovery organization based on innovative medicinal chemistry capabilities, aiming to be a preferred partner to pharmaceutical and biotech firms by providing therapeutic leads through out-licensing. Their discovery platform provides a competitive advantage for rapid medicinal chemistry optimization and intellectual property enhancement.
- May 2024Grant (prize money)$500K
- Sep 2015Grant (prize money)$225K
- Aug 2013Grant (prize money)$374.5K
- 2013Grant (prize money)$374.5K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics in Pennsylvania is moving
A read on the academic research around Bioinformatics in Pennsylvania — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 274 papers.
University of Pennsylvania and Penn State lead Pennsylvania's bioinformatics research, focusing optimistically on single-cell transcriptomics and genomics, with breakthroughs dominating recent output since 2020.
- University of Pennsylvania164
- Pennsylvania State University80
- California University of Pennsylvania26
- Hospital of the University of Pennsylvania11
- Transcriptome1→15
- Gene3→11
- Genome3→8
- Gene expression1→4
- Exon1→3
- Transcriptome1→8
- Genome1→6
- Cancer1→3
- Disease1→6
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.